Gene and peptide structure
Subsequent cloning of the human, porcine (Burghardt et al., 1994a) and mouse (Koskimies et al., 1997; Zimmermann et al., 1997) genomic sequences showed that RLF/Ley-I-L is encoded by a single-copy gene, comprising only two exons with the single intron interposing within the open-reading frame encoding the C (connecting) peptide domain (see below). This exonic organization is similar to that for the relaxin and insulin genes. In humans, the RLF/Ley-I-L gene has been localized to the short arm of chromosome 19 (p13.2-p12; Burghardt et al., 1994b) . Although studies on the regulation of the RLF gene are still very preliminary, the promoter region of the mouse gene does not appear to contain marked homology to other known genes. Computer analysis has identified motifs for binding the constitutive transcription factor SP1 and possibly also for steroidogenic factor 1 (Koskimies et al., 1997; Zimmermann et al., 1997) , although experimental work is necessary to examine these more fully. However, constructs comprising about 0.7 kb of the region upstream of the transcription start site appear to be sufficient to permit expression specifically in Leydig cells (Koskimies et al., 1997) .
The primary structure of the mRNA transcript produced from this gene has been analysed in a number of species (porcine, Adham et al., 1993; human, Burghardt et al., 1994a; mouse, Pusch et al., 1996; rat, W. Pusch and R. Ivell, unpublished; bovine, Bathgate et al., 1996; sheep, Roche et al., 1996; and marmoset monkey, R. Zarreh-Hoshyari-Khah, A. Einspanier and R. Ivell, unpublished) . Although there is variability between species such that, for example, the mouse cDNA sequence shares only 51% homology with the human sequence -a fact that prevents some probes from hybridizing across species -all encode polypeptides of about 14 kDa with very similar structural organization (Fig. 1) . This is the structure shared by all members of the insulin-IGF-relaxin family. First, there is a classic signal peptide domain at the N-terminus, which is most likely used to traffic the molecule into the endoplasmic reticulum and hence into the secretory pathway. This is followed by a polypeptide which, by homology of cysteine residues and potential endopeptidase cleavage signals, is separable into B, C (connecting) and A domains, using the nomenclature defined for the proinsulin molecule.
There is hardly any information on the RLF/Ley-I-L molecule at the peptide level. Antibodies have only recently become available (for example, , and these have not yet provided information as to whether the RLF molecule is indeed secreted, or if it is processed into its component moieties (as are insulin or relaxin in most species), or produced as an unprocessed molecule (as are IGF-I and IGF-II). That RLF is most probably secreted from the cells where it is made is shown
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indirectly by the structure of the N-terminal signal peptide moiety, and by the fact that secretion of marmoset RLF has been demonstrated when the protein is produced biotechnologically in baculovirus-infected insect cells (R. Zarreh-Hoshyari-Khah and R. Ivell, unpublished). Finally, the demonstration that high affinity RLF-specific receptors appear to be present in the mouse uterus (Büllesbach and Schwabe, 1995) , a tissue with little or no local RLF production, would lead one to assume that RLF is indeed a secreted peptide factor like all other members of the insulin-IGF-relaxin family, and presumably able to enter the circulation or otherwise reach receptors in target tissues.
Cleavage of the full-length polypeptide can only be inferred from the homology of the endopeptidase cleavage signals to those found also in the relaxin molecules from various species, and which are thought to be substrates for enzymes such as furin (Renegar et al., 1996) . Although it seems likely that these are cleaved in vivo -the human molecule, chemically synthesized like relaxin as an A-B heterodimer (Büllesbach and Schwabe, 1995) and shown to interact with specific receptors would support this viewpoint -it should be noted that both IGFs are bioactive without cleavage of the C-domain, and that porcine prorelaxin is just as bioactive as its cleaved product (Layden and Tregear, 1996) . One of the most interesting features of the RLF peptide structure is the conservation of a peptide epitope in the middle of the B-domain, comprising the motif X-R-X-X-X-R-X, which is very similar to the epitope identified as the receptor binding site of relaxin (Büllesbach et al., 1992) . The only difference is that in all RLF molecules this feature is shifted four amino acids further C-terminal to the conserved cysteine residue. The availability of this motif in approximately the same position on a molecule whose three-dimensional structure is likely to be very similar to that of relaxin probably accounts for the moderate but specific affinity of RLF for relaxin receptors, but not for insulin or IGF receptors (Büllesbach and Schwabe, 1995) .
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Leydig cell expression
The RLF/Ley-I-L gene is expressed as a common, approximately 0.9 kb transcript in all testicular tissues so far examined. It was originally identified by differential cloning in the porcine testis in a study looking for testis-specific transcripts (Adham et al., 1993) , and independently in the mouse testis (Pusch et al., 1996) in a study looking for clones upregulated preferentially in the azoospermic mutant w/w v mouse compared with wild type mice. In situ hybridization in the porcine (Adham et al., 1993) , mouse (Pusch et al., 1996) , bovine (Bathgate et al., 1996) , sheep (Roche et al., 1996) , and human testis confirm that, within the testis, RLF is expressed exclusively in the interstitial Leydig cells (Fig. 2) . This has also been confirmed in studies using purified Leydig cells from mouse testis in which expression of RLF was greatly enriched compared with whole testis (Pusch et al., 1996; Zimmermann et al., 1997) . Also, mouse Leydig tumour cells (MA10) show expression of the RLF transcript (Pusch et al., 1996; Zimmermann et al., 1997) . Most recently, immunohistochemistry in the human ( Fig.2; Ivell et al., 1997) , mouse and marmoset (M. Balvers, A. Einspanier and R. Ivell, unpublished) confirm that, within the testis, only the Leydig cells express the RLF peptide.
The RLF transcript is exceedingly common. Calculations for the bovine testis suggest that some 5% of all transcription in Leydig cells goes to making this peptide. However, the adult Leydig cell has characteristically little rough endoplasmic reticulum and is virtually devoid of classic 100-160 nm dense-core secretory granules, features which should be prominent in a cell secreting a large amount of a secretory polypeptide. Assuming that RLF is indeed secreted, the only explanation is that RLF is made not via the regulated granule-dependent secretory pathway, but via the constitutive pathway, much as hCG is produced in the placenta. This implies that RLF is trafficked via the Golgi directly in small vesicles to the plasma membrane, where it is released in a relatively unregulated fashion. In support of an unregulated mode of production is the observation that in MA10 cells and primary mouse Leydig cells in culture, none of the classic Leydig cell effectors and secretogogues (hCG, phorbol esters, atrionatriuretic peptide) influence the level of RLF mRNA in these cells (Pusch et al., 1996) . Furthermore, in a clinical study evaluating immunoreactive RLF in the testes of patients with a variety of severe and less severe disorders, there appeared to be no significant fluctuation in staining intensity, as was observed with the Leydig cell marker, 3β-hydroxysteroid dehydrogenase . Thus, irrespective of the physiological environment, the RLF gene appears to be expressed constitutively in the adult Leydig cell and may leave the cell via the unregulated pathway.
However, the RLF gene does appear to be developmentally regulated. Analysis of rat and mouse testes through development show that although RLF mRNA can be detected by PCR in the mouse embryo 13 days post coitum , the principal upregulation occurs during puberty (Pusch et al., 1996; Zimmermann et al., 1997) . In agreement with this observation is the finding that in the adult hypogonadal (hpg) mouse, whose gonads remain effectively in a prepubertal state because of a deletion in the GnRH gene, RLF mRNA and peptide are undetectable. Only after several days treatment with hCG, which forces the testes to differentiate, does RLF become detectable (R. Ivell, M. Balvers, H. Charlton and A. N. Spiess, unpublished).
Ovarian expression
In the original studies that analysed RLF gene expression by northern hybridization, RLF was considered to be exclusively a testis-specific gene (Adham et al., 1993; Pusch et al., 1996) . Tashima et al. (1995) , however, were able to show a weak northern signal in human ovary and trophoblast, and Zimmermann et al. (1997) detected a similar signal in the mouse ovary. However, neither of these signals were comparable in magnitude to those identified in the ruminant ovary (Bathgate et al., 1996; Roche et al., 1996) . Here, northern hybridization indicated that RLF mRNA was present in the ovary at levels as great or greater than those in the testis. In situ hybridization showed that the strongest signals were not only in the theca cells of preovulatory and atretic follicles (Bathgate et al., 1996) , but also in the corpus luteum of the mid-late cycle and in pregnancy. Interestingly, the RLF gene was expressed only weakly in the corpus luteum of the early cycle, and was completely downregulated in corpora lutea undergoing luteolysis. We have recently been able to confirm a comparable pattern of expression in marmoset and mouse ovaries using immunohistochemistry with RLF specific antibodies (R. Ivell, A. Einspanier and M. Balvers, unpublished).
The very high expression of the RLF gene in the ruminant ovary, by comparison with other species, is interesting since it suggests that only ruminants lack a gene for the related hormone, relaxin (Hartung et al., 1995) , which in most other mammals is also expressed in ovarian theca and luteal cells and plays an important role in female reproduction. Yet ruminants do appear to have specific relaxin receptors, and exhibit a characteristic relaxin-dependent physiology (Anderson et al., 1995) . In view of the ability of human RLF to interact with relaxin receptors (see above), it is attractive to speculate that RLF may be functionally substituting for relaxin in ruminants such as the sheep and cow.
It was pointed out in the context of the Leydig cell that RLF gene expression appears to be constitutive, once differentiation of the cell had occurred. This appears also to be true for the bovine ovarian theca cell, in which in situ hybridization shows no change in the level of RLF mRNA expression, irrespective of whether the theca cells are parts of preovulatory or atretic follicles (Bathgate et al., 1996) .
Other tissues
Very little is known about RLF expression in other tissues. Except in the human where a very weak signal is detectable in trophoblast (Tashima et al., 1995) , northern hybridization has consistently failed to show any specific RLF transcripts in any tissues other than testis or ovary. In a more extensive study of bovine tissues using RT-PCR, Bathgate et al. (1996) were able to detect RLF specific signals in endometrium and myometrium of the uterus both in the cycle and in pregnancy, and in caruncle and chorion, as well as in epididymis. Very weak signals were also detectable in heart and lung, and, suprisingly, there was a moderate signal in the hypothalamus. Considering that specific RLF receptors were detected in the mouse brain in a heterologous assay using a human RLF peptide (Büllesbach and Schwabe, 1995) , this last observation may point to a role for RLF also in the central nervous system.
Receptors and function
All the evidence at present points to RLF being a novel secreted factor with a role to play in the testis and in the ovary. Certainly for the testis and possibly also for the ovary, based on the level of gene transcription and the relative intensity of immunostaining, RLF should be secreted at a level that is likely to have not only local effects but also systemic effects. So far, relevant receptors have only been sought for and found in mouse uterus and brain (Büllesbach and Schwabe, 1995) using a heterologous assay based on a synthetic A-B heterodimeric human peptide. Additionally, there is evidence for local systems in the uterus, possibly also involving the placenta during pregnancy, and in the brain. Altogether, this is a pattern of expression very reminiscent of what is known for the related hormone, relaxin.
As with relaxin and the other members of this family, including the other newly described member, placentin (Koman et al., 1996) , we might expect that RLF is involved in growth and differentiation, particularly of reproductive tissues. The observation that its expression appears to be constitutive rather than regulated may preclude it from acute feedback roles, such as one finds for insulin or for inhibin. However, one should not ignore the possibility that a constitutive factor can be acutely regulated through the agency of specific binding proteins, as in the case of the IGFs. Supporting a role in differentiation is the finding that RLF is a marker for a specific stage of differentiation in the Leydig cell, and possibly also for theca/luteal cells. Adham and coworkers have recently succeeded in producing knock-out mice whose RLF/Ley-I-L gene has been ablated. Preliminary reports suggest that only the males are impaired and show a marked disturbance in spermatogenesis . A full study of these mice, including possible subtle effects in development, is eagerly awaited.
Conclusion
The relaxin-like factor, RLF, is a highly expressed novel member of the insulin-IGF-relaxin hormone family that is specifically expressed in reproductive tissues with a common pattern in males and females of all mammals so far investigated. Like the related hormone, relaxin, it is to be expected that besides certain principal functions, possibly in the differentiation of reproductive tissues, it may have other local or more subtle functions, for example within the brain. At the current stage of research, the tools available to investigate these functions are extremely limited. It is therefore of paramount importance to develop bioactive peptides, agonists and antagonists, and to establish sensitive immunoassays and receptor assays, as well as appropriate in vivo and in vitro test systems in which to analyse this new factor. Only then will we be able to allocate it an appropriate place in the menagerie of reproductive endocrinology. 
